BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 4 February 2011 at 11.45 Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of the notifications regarding changes in holdings in accordance with Chapter 2, Section 9 of the Finnish Securities Markets Act, described below. The notifications received by the Company concern the changes in holdings of Invesco Limited (through Invesco Fund Managers Limited) ("Invesco"). The mentioned change in holdings is related to the Combination Agreement entered into on 10 January 2011 among the Company, Synosia Therapeutics Holding AG ("Synosia") as well as Synosia's shareholders and warrant holders, described in more detail in a stock exchange release issued on 11 January 2011. As described in detail in Biotie's stock exchange release issued on 2 February 2011, Biotie's Extraordinary General Meeting has on 1 February 2011 passed resolutions necessary for the completion of the transaction and the other prerequisites for the completion of the transaction have been fulfilled, and the Company has issued 161,448,371 shares to the shareholders and warrant holders of Synosia as consideration for the entire issued share capital and outstanding warrants of Synosia (the "Transaction"). In connection with the Transaction, the Company issued 14,912,155 new shares to Synosia to be held in treasury and used to satisfy future potential exercise of Synosia's options. The new shares have been registered on 3 February 2011. As a consequence of the Transaction Invesco's holding of shares and votes in the Company decreased below 5 % as follows: Name Number of Number of Number of Share of Share of shares before voting rights shares and share capital voting rights Transaction before voting rights after after Transaction after Transaction Transaction Transaction (%) (%) Invesco 14,432,000 14,432,000 14,432,000 4,10 4,10 Limited (through Invesco Fund Managers Limited) On the date hereof, the registered number of shares in Biotie Therapies Corp. is 352,364,457. Of these shares 29,659,239 are held by the Company or its group companies. Turku, 4 February 2011 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900 e-mail:virve.nurmi@biotie.com DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media www.biotie.com [HUG#1485493]
Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act
| Source: Biotie Therapies